Appendix 4C

31 January 2019

Melbourne, Australia and Leatherhead, UK

CLINUVEL PHARMACEUTICALS LTD, a global biopharmaceutical company focused on developing and delivering treatments for patients with a range of severe genetic and skin disorders, today announced its Appendix 4C – Quarterly Cashflow report for the period 01 October to 31 December 2018. All figures are rounded and reported in Australian dollars.